Updated EU CTIS Guide Offers Workaround To Protect ‘Commercially Confidential’ Dosing Data

 
• By Vibha Sharma
  
Generate a summary of this article
Listen to this article
Beta

EU regulators explain how sponsors who are running integrated Phase I/Phase II trials can overcome default transparency settings in the Clinical Trials Information System to protect the disclosure of dosing details if these contain commercially confidential information.

Clinical trial
The Default Setting In CTIS Is To Make Trial Data/Documents Public At The First Opportunity • Source: Alamy

EU regulators have issued updated guidance explaining how sponsors of Category 2 trials under the Clinical Trials Regulation (CTR) can prevent the automatic public disclosure of dosing data in their study applications submitted via the Clinical Trials Information System (CTIS) in cases where such data are considered commercially confidential. 

Key Takeaways

  • EU regulators have come up with a workaround to protect the automatic disclosure of dosing data in integrated Phase I/II trials via the Clinical Trials Information System if such data are considered commercially confidential.

The guideline, jointly developed by the European Commission, the European Medicines Agency and the EU Heads of Medicines Agencies, was...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Clinical Trials

Canada Cuts Red Tape With Single Ethics Review For Trials

A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.

Diversity Action Plans: What To Submit And When

 
• By Nielsen Hobbs

With the deadline for comments on the US FDA’s draft guidance less than a month away, the Pink Sheet offers an infographic outlining what the agency is expecting in diversity action plans and when that might be implemented.

India Tightens Oversight Of CROs With Mandatory Registration

 
• By Vibha Sharma

Contract research organizations (CROs) in India must gear up to comply with new registration requirements coming into effect in April 2025 that aim to enhance the quality and integrity of clinical trials, as well as of any bioavailability and bioequivalence studies conducted by them.

UK Expedites Cost Negotiations For Companies Conducting ATMP & Early Phase Trials

 
• By Neena Brizmohun

Companies dealing with commercial costings or contracts with the National Health Service for early phase clinical trials or trials of advanced therapy medicinal products should soon be able to conclude their negotiations more quickly.

More from R&D

India Tightens Oversight Of CROs With Mandatory Registration

 
• By Vibha Sharma

Contract research organizations (CROs) in India must gear up to comply with new registration requirements coming into effect in April 2025 that aim to enhance the quality and integrity of clinical trials, as well as of any bioavailability and bioequivalence studies conducted by them.

Clinical Trial Diversity Action Plans Need Timely FDA Feedback, Groups Say

 
• By Sue Sutter

The agency also should explain the potential consequences for sponsors if enrollment goals are not met, stakeholders say in comments on the DAP draft guidance. Some commenters urged the FDA to apply waiver criteria flexibly, especially for rare diseases.

How To Decarbonize Pharma R&D

 
• By Francesca Bruce

As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.